The 30-second summary
- The question: frail people have more to gain from fewer heart attacks, and more to lose from side effects and weight loss. Does semaglutide still come out ahead?
- The study: a post hoc analysis of the SELECT trial, 17,604 adults with heart disease and overweight but no diabetes, published in JAMA Cardiology on 16 September 2026.
- The answer: benefits held across frailty levels. Frailty was 2.46 times as likely to improve on semaglutide than on placebo, and the frailest gained most in quality of life.
- The limits: a secondary analysis, an average age of 61.6, and the most frail group's heart result on its own was not statistically clear.
Why frailty is the right question
Doctors worry about prescribing weight-loss medicines to frail people for good reasons. Nausea and a small appetite can tip someone already at the edge into eating too little. Weight that comes off includes some muscle. And a person who falls easily has little to spare.
SELECT, published in 2023, was the trial that showed semaglutide 2.4 mg weekly, the Wegovy dose, cut major heart events by 20% in people with heart disease and overweight (Lincoff et al.). This new analysis asked whether that held for its frailer members.
How was frailty measured?
The researchers built a 31-item frailty index from data collected at the start of the trial. It counts accumulated health deficits, so a higher score means more of them. They then split participants into three groups.
| Group | Frailty index | People |
|---|---|---|
| Not frail | up to 0.210 | 5,432 (31%) |
| More frail | 0.211 to 0.310 | 8,349 (47%) |
| Most frail | 0.311 or higher | 3,823 (22%) |
The average age was 61.6, and 72.3% were men.
What did the study find?
Heart events. As expected, the frailer the group, the more heart attacks, strokes and heart deaths it had. Semaglutide's effect against placebo looked similar across groups.
| Group | Hazard ratio for heart events |
|---|---|
| Not frail | 0.84 (0.65 to 1.07) |
| More frail | 0.70 (0.59 to 0.82) |
| Most frail | 0.92 (0.76 to 1.10) |
The test for a real difference between groups was not significant. Semaglutide also reduced heart failure events, hospital admissions for any cause and deaths from any cause, regardless of frailty.
Quality of life. The benefit on a standard quality of life score was larger in frailer people.
Frailty itself. Between the start and week 104, people on semaglutide were 2.46 times as likely to move to a less frail category (OR 2.46, 95% CI 1.80 to 3.37) and about half as likely to move to a more frail one (OR 0.47).
Side effects. The extra risk of stopping semaglutide because of side effects, compared with placebo, was smaller in frailer people than in the least frail. In SELECT as a whole, 16.6% on semaglutide stopped for side effects against 8.2% on placebo, so stopping was still common.
The authors conclude that frailty "should not preclude consideration" of semaglutide in eligible people, and call the findings hypothesis generating.
A second study points the same way
On 7 October 2026, Diabetes, Obesity and Metabolism published a US Veterans Health study of adults with type 2 diabetes (Zhang et al.). It matched 73,592 people starting a GLP-1 medicine with 73,592 starting a DPP-4 inhibitor, an older diabetes tablet, and followed them for about 27 months.
The GLP-1 group had slightly less worsening of frailty and a 13% lower rate of falls (incidence rate ratio 0.87). The advantage faded in people who were severely frail at the start. As an observational study, it shows a link, not cause.
What this study does not tell us
- It was not designed for this. Post hoc analyses look back at a trial built to answer another question.
- The most frail group's result was uncertain. Its confidence interval for heart events crossed 1, so on its own it does not prove benefit there.
- Frailty here is a count of conditions, not strength. The abstract reports no grip strength, walking speed or muscle measures.
- The population was narrow. Mostly men in their early 60s with heart disease and no diabetes. Several authors are Novo Nordisk employees, and the company makes Wegovy.
What it means if you are older or frail
As of October 2026, this is randomised trial evidence, analysed after the fact, that frailty alone is not a reason to rule semaglutide out. It is not evidence that it is right for every frail person. That is a conversation with your prescriber, and it is worth raising your weight, appetite, falls and how much you can do day to day.
Two habits help. First, eat enough protein even when hungry for little, which matters more as appetite shrinks; protecting muscle on a GLP-1 sets out how. Second, keep your muscles working: strength training on a GLP-1 does not need a gym. If a meal is hard to finish, start with the protein. If you are losing weight faster than planned or feel weaker, tell your prescriber.
Sources
- Ostrominski JW, Plutzky J, Scirica BM, et al. Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial. JAMA Cardiol 2026. PubMed
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023. PubMed
- Zhang S, Lingvay I, Mansi I. Association of GLP1-Receptor Agonist Use With Frailty and Falls in Adults With Type 2 Diabetes. Diabetes Obes Metab 2026. PubMed